IV NAD+ drips promise mitochondrial renewal. A full review of the human evidence finds how little of that is proven

Edited by Samael A. Tejada, Founder & Editor-in-Chief

The mechanism is beautiful and mostly true: feed the coenzyme, feed the mitochondria. The human evidence for doing it through a drip, reviewed end to end, is a handful of small uncontrolled studies and a list of things nobody has measured yet. Both halves of that sentence belong on the clinic wall.

What did the review actually survey?

Alangari and colleagues conducted a structured narrative review of literature published January 2018 through March 2026 (PubMed and Google Scholar), including human clinical data on IV NAD+ or IV NAD+ precursor administration plus directly relevant mechanistic and safety evidence; a formal systematic review and meta-analysis was not considered appropriate given the limited randomized trials and substantial heterogeneity. Their summary verdict: despite increasing commercial use of IV NAD+ therapy in wellness settings, the clinical evidence supporting its efficacy and long-term safety remains limited. Available human evidence consists primarily of small uncontrolled studies, observational investigations and isolated case reports.

What benefits and harms are actually documented?

On the benefit side: short-term IV NAD+ or NMN administration has been associated with transient increases in circulating NAD+ levels and changes in selected biomarkers related to oxidative stress, inflammation and cellular metabolism, and limited exploratory reports describe self-reported improvements in sleep-related outcomes and neurologic symptoms. The authors stress the clinical significance remains uncertain — small sample sizes, lack of placebo controls, heterogeneous methodologies, short follow-up. On the harm side: reported adverse effects include nausea, cramping, flushing and chest discomfort, while long-term safety data are lacking. Also unresolved is pharmacology itself: human studies have not established the distribution of the intact NAD+ molecule across organs, and rapid extracellular metabolism may contribute substantially to what blood tests measure afterward.

Does the 'NAD+ declines with age' premise hold?

Less cleanly than the marketing suggests. The review notes that age-associated NAD+ decline has been associated with mitochondrial dysfunction and impaired metabolic regulation — and, in the same breath, that recent large-scale human data indicate whole-blood NAD+ concentrations do not decline with healthy aging per se. Mechanistically, raising NAD+ availability can support the electron transport chain and, via SIRT1 activation of PGC-1alpha, mitochondrial biogenesis — in the preclinical and mechanistic literature. The distance between that machinery and a wellness outcome in a person paying for a drip is exactly the distance the human trial record has not yet crossed. Clinics offering IV NAD+ are offering a biologically plausible intervention with transient biomarker effects, documented short-term side effects, and unproven clinical benefit; readers should price it accordingly.

Where the evidence stands

• Established: NAD+ is a major coenzyme in cellular metabolism, mitochondrial function, DNA repair and stress-response signaling; IV administration transiently raises circulating NAD+ levels; and reported short-term adverse effects include nausea, cramping, flushing and chest discomfort.
• Preliminary: Per the Frontiers in Aging narrative review (Sep 10, 2026; DOI 10.3389/fragi.2026.1887175; literature Jan 2018–Mar 2026), human IV NAD+/precursor evidence is sparse — small uncontrolled studies, observational investigations and case reports — with biomarker changes in oxidative stress, inflammation and metabolism and exploratory self-reported sleep and neurologic improvements of uncertain clinical significance.
• Contested: The founding premise as marketed: recent large-scale human data cited by the review indicate whole-blood NAD+ concentrations do not decline with healthy aging per se.
• Absent: Randomized placebo-controlled outcome trials of IV NAD+ for wellness or aging, long-term safety data, and established distribution of intact NAD+ to human organs.